Suppr超能文献

挑战外科定论:10 年慢性华法林治疗患者开放式腹股沟疝修补术安全性经验。

Challenging a surgical dictum: results from a 10-year experience on the safety of open inguinal herniorrhaphy in patients on chronic warfarin therapy.

机构信息

Department of General Surgery, Mayo Clinic Arizona, 5777 E. Mayo Boulevard, Phoenix, AZ, 85054, USA.

出版信息

Hernia. 2015 Feb;19(1):83-7. doi: 10.1007/s10029-014-1257-1. Epub 2014 Apr 23.

Abstract

BACKGROUND

Previous reports document the safety of open inguinal herniorrhaphy in patients on chronic warfarin therapy; however, the practice remains controversial. This study is a 10-year update of our experience.

METHODS

A retrospective review of 1,839 consecutive patients undergoing open inguinal hernia repair was conducted from 2000 to 2010. All patients on chronic warfarin therapy were included. Three groups: continuation (CW), discontinuation (DW) and case-matched control (C) not on warfarin therapy were compared for operative details and postoperative complications.

RESULTS

One hundred and fifty-eight patients were on chronic warfarin therapy. Of these, 40 patients (25%) continued on warfarin during the perioperative period (CW). Average preoperative international normalized ratio (INR) was 2.15 ± 0.76 for CW and 1.38 ± 0.42 for DW, p < 0.001. Mean operative times were equivalent between all three groups (88 min CW vs. 85 min DW vs. 79 min C, p = 0.518). Although CW patients experienced higher incidences of both hematoma and urinary retention overall, no statistically significant differences in complication rates were seen between the three groups (hematoma = 10 vs. 8% DW vs. 5% C, p = 0.703; urinary retention = 15 vs. 10% DW vs. 8% C, p = 0.541). Comparing patients by INR, there were no statistically different postoperative complication rates, particularly for hematoma (8% INR <2 vs. 9.5% INR = 2-3 vs. 20% INR >3, p = 0.65).

CONCLUSION

Maintenance of warfarin therapy during the perioperative period for open inguinal herniorrhaphy results in equivalent operative times and postoperative complications as discontinuation.

摘要

背景

先前的报告记录了在接受慢性华法林治疗的患者中进行开放式腹股沟疝修补术的安全性;然而,该实践仍然存在争议。本研究是对我们经验的 10 年更新。

方法

对 2000 年至 2010 年期间连续 1839 例接受开放式腹股沟疝修补术的患者进行回顾性分析。所有接受慢性华法林治疗的患者均包括在内。比较了继续(CW)、停止(DW)和未接受华法林治疗的病例匹配对照组(C)三组的手术细节和术后并发症。

结果

158 例患者正在接受慢性华法林治疗。其中,40 例(25%)在围手术期继续服用华法林(CW)。CW 的平均术前国际标准化比值(INR)为 2.15 ± 0.76,DW 为 1.38 ± 0.42,p < 0.001。三组的平均手术时间相当(CW 为 88 分钟,DW 为 85 分钟,C 为 79 分钟,p = 0.518)。尽管 CW 患者总体上血肿和尿潴留的发生率更高,但三组之间的并发症发生率无统计学差异(血肿= 10% vs. DW = 8% vs. C = 5%,p = 0.703;尿潴留= 15% vs. DW = 10% vs. C = 8%,p = 0.541)。按 INR 比较患者,术后并发症发生率无统计学差异,尤其是血肿(INR <2 = 8%,INR = 2-3 = 9.5%,INR >3 = 20%,p = 0.65)。

结论

在开放式腹股沟疝修补术围手术期维持华法林治疗与停药相比,可产生相当的手术时间和术后并发症。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验